Bcl-2 family proteins are essential for platelet survival
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Platelets are relatively short-lived, anucleated cells that are essential for proper hemostasis. The regulation of platelet survival in the circulation remains poorly understood. The process of platelet activation and senescence in vivo is associated with processes similar to those observed during apoptosis in nucleated cells, including loss of mitochondrial membrane potential, caspase activation, phosphatidylserine (PS) externalization, and cell shrinkage. ABT-737, a potent antagonist of Bcl-2, Bcl-X(L), and Bcl-w, induces apoptosis in nucleated cells dependent on these proteins for survival. In vivo, ABT-737 induces a reduction of circulating platelets that is maintained during drug therapy, followed by recovery to normal levels within several days after treatment cessation. Whole body scintography utilizing ([111])Indium-labeled platelets in dogs shows that ABT-737-induced platelet clearance is primarily mediated by the liver. In vitro, ABT-737 treatment leads to activation of key apoptotic processes including cytochrome c release, caspase-3 activation, and PS externalization in isolated platelets. Despite these changes, ABT-737 is ineffective in promoting platelet activation as measured by granule release markers and platelet aggregation. Taken together, these data suggest that ABT-737 induces an apoptosis-like response in platelets that is distinct from platelet activation and results in enhanced clearance in vivo by the reticuloendothelial system.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, targeting BCL-XL with conventional inhibitors causes severe thrombocytopenia, limiting their clinical use [5–7].”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [6]
In the citing paper
“a potential clinical limitation of BCL-XLi is the fact that these inhibitors can cause on-target, reversible thrombocytopenia (Zhang et al., 2007).”
From A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution (2017) · cites this paper as Zhang et al., 2007
Citations
Cites
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“ABT-737 is a small molecule antagonist of the prosurvival Bcl-2 family proteins Bcl-XL, Bcl-2, and Bcl-w that induces apoptosis in tumor cells in a mitochondria-dependent fashion.(18) Treatment of ABT-737 in dogs leads to a rapid, dosedependent decrease in circulating platelets that return to baseline within 72-h post…”
BackgroundSelf-citationA receptor for phosphatidylserine-specific clearance of apoptotic cells
Fadok, V. A., Bratton, D. L., Rose, D. M., Pearson, A., Ezekewitz, R. A. B., & Henson, P. M. (2000) · Nature · doi:10.1038/35011084 · Cited by 1,491 · cited 1×
“PS externalization on cells has also been shown to signal the specific engulfment of these unwanted cells by phagocytes leading to clearance from the circulation .(9,15,25) Finally, the fact that the enantiomer negative control does not activate the apoptotic cascade at equivalent concentrations supports the notion th…”
BackgroundThe biogenesis of platelets from megakaryocyte proplatelets
Patel, S. R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26891 · Cited by 603 · cited 1×
“The similarities between platelet biogenesis from megakaryocytes and apoptosis include membrane blebbing, membrane condensation, DNA fragmentation, cell shrinkage, and ultimately the formation of apoptotic bodies.(5,6) The consequence of this apoptotic process is that each mature megakaryocyte fragments into thousands…”
BackgroundThe platelet release reaction: granules' constituents, secretion and functions
Rendu, F., & Brohard-Bohn, B. (2001) · Platelets · doi:10.1080/09537100120068170 · Cited by 599 · cited 4×
“Upon platelet activation, a series of granules are released that are essential for the full activation response.(21) To further investigate other direct effects of ABT-737 on platelet dynamics, isolated platelets were treated with ABT-737 and classical markers of granule release were monitored.”
BackgroundMethodInfluentialProgrammed cell death and Bcl-2 protection in the absence of a nucleus.
Jacobson, M. D., Burne, J. F., & Raff, M. C. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06459.x · Cited by 552 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundMartin, S. J., Finucane, D. M., Amarante-Mendes, G. P., O'Brien, G. A., & Green, D. R. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28753 · Cited by 372 · cited 1×
“Previous studies have shown that apoptotic agents promote morphological changes in anucleated cytoplast that resemble characteristics of programmed cell death.(23,24) In platelets, the morphological changes of apoptosis closely resemble those of activation, including PS externalization, microparticle release (i.”
BackgroundWolf, B. B., Goldstein, J. C., Stennicke, H. R., Beere, H., Amarante-Mendes, G. P., Salvesen, G. S., & Green, D. R. (1999) · Blood · doi:10.1182/blood.v94.5.1683 · Cited by 323
The role of the Bcl-2 protein family in cancer
Coultas, L., & Strasser, A. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00129-3 · Cited by 242 · cited 1×
“The process of apoptosis can be viewed as a cascade of events initiating from the accumulation of a death signal(s), release of apoptotic factors from the mitochondria, activation of initiator/effector caspases, ultimately leading to cell death.(16) Our studies demonstrate that ABT-737 initiates the apoptotic cascade…”
BackgroundA Simple Nonradioisotope Technic for the Determination of Platelet Life-Span
Stuart, M. J., Murphy, S., & Oski, F. A. (1975) · New England Journal of Medicine · doi:10.1056/nejm197506192922502 · Cited by 242 · cited 1×
“released into the circulation, platelets rapidly age with a halflife of 4–5 days.(7,8) As platelets age, they lose their ability to function and are subsequently removed from circulation.”
BackgroundRole of platelets in thrombosis and hemostasis
Packham, M. A. (1994) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y94-043 · Cited by 215 · cited 2×
“Subsequent platelet activation, granule release, and aggregation are essential for the formation of a hemostatic plug that limits blood loss and stimulates repair.(2) There are several morphological changes associated with platelet activation that are reminiscent of nucleated cell apoptosis.”
Background
Cited by
Items 301–400 of 452
The Effects of Cyclosporine on Platelet Function and Cyclooxygenase Expression in Normal Dogs
Thomason, J., Lunsford, K. V., Stokes, J. V., Pinchuk, L. M., Wills, R. W., Langston, V. C., Pruett, S., & Mackin, A. J. (2012) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2012.01025.x · Cited by 13
Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors
Leverson, J. D. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1050155 · Cited by 13
Wu, Y.-H., Chen, H., Hong, W.-C., Wei, C., & Pang, J. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116290 · Cited by 12
“In previous reports, pathways involved PI3K, caspase and Bcl-2 family proteins for megakaryocytes survival were mentioned as the possible mechanisms of CIT [11,13,27].”
BackgroundStayin’ alive: BCL-2 proteins in the hematopoietic system
Zehnle, P. M. A., Wu, Y., Pommerening, H., & Erlacher, M. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.03.006 · Cited by 12
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas
Watanabe, T. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504710 · Cited by 15
“Despite the promising activity of ABT-737 in vitro and in vivo, ABT-737-induced platelet destruction and the resultant thrombocytopenia raise concerns about possible adverse effects of high-dose or long-term treatment with ABT-733 [60,61].”
Rahman, S. F. A., Azlan, A., Lo, K. W., Azzam, G., & Mohana‐Kumaran, N. (2022) · Discover Oncology · doi:10.1007/s12672-022-00470-9 · Cited by 12
“Inhibition of BCL-XL may result in thrombocytopenia [12, 13] and co-inhibition of BCL-XL and MCL-1 can result in fatal hepatotoxicity [14].”
BackgroundGuo, Z., Song, T., Xue, Z., Liu, P., Zhang, M., Zhang, X., & Zhang, Z. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105105 · Cited by 12
Wang, S., Mao, Y. Q., Xi, S., Wang, X., & Sun, L. (2016) · The Anatomical Record · doi:10.1002/ar.23454 · Cited by 12
“However, increasing ABT737 dosage can lead to rapid thrombocytopenia and other side effects (Mason et al., 2007; Zhang et al., 2007).”
BackgroundDesialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment
Zheng, S. S., & Perdomo, J. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46110709 · Cited by 12
“Two seminal studies showed that proteins of the BCL2 family are the key players in this pathway [42,44].”
Golbashirzadeh, M., Heidari, H. R., & Khosroushahi, A. Y. (2022) · Gene Reports · doi:10.1016/j.genrep.2022.101614 · Cited by 12
Pyrogallol Induces Apoptosis in Human Platelets
Bruges, G., Venturini, W., Crespo, G., & López-Zambrano, M. (2018) · Folia Biologica · doi:10.14712/fb2018064010023 · Cited by 11
“Furthermore, the intrinsic apoptosis pathway plays an essential physiological role in platelet survival, and is an important regulator of platelet life span in vivo (Zhang et al., 2007; Kile, 2009).”
BackgroundGao, Q., Xiang, Y., Chen, Z., Zeng, L., Ma, X., & Zhang, Y. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0690 · Cited by 11
“Platelets were treated with βγ-CAT (2–50 nM, 30 min) or ABT-737 (1–25 μM, 180 min) at 22°C, and then lysed in lysis buffer.”
BackgroundInfluentialDiscovery of potent and selective Bcl-2 inhibitors with acyl sulfonamide skeleton
Wang, B., Feng, W., Wang, J., Dong, Y., Liu, Y., Yao, Y., Zhang, J., Shi, W. Q., Liu, L., Zhang, H., et al. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116350 · Cited by 11
Self-citationTargeting Survival Pathways in Lymphoma
Paoluzzi, L., & O’Connor, O. A. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6706-0_5 · Cited by 14
Biswas, S., Killick, E., Jochemsen, A. G., & Lunec, J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892924 · Cited by 13
“BCL-xL is essential for circulating platelet survival [48-50], whereas Mcl-1 is mainly responsible for the survival of neutrophils [51] that have a comparatively higher rate of spontaneous apoptosis caused by constitutive expression of BAK [52].”
BackgroundTranscriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLPreprint
Mohanty, V., Baran, N., Huang, Y., Ramage, C. L., Cooper, L., He, S., Iqbal, R., Daher, M., Tyner, J. W., Mills, G. B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.27.577579 · Cited by 12
A human neuron Alzheimer’s disease model reveals barriers to senolytic translatability
Walton, C. C., Wang, E. Y., Lee, S., Siebrand, C. J., Bergo, N. J., Mayeri, Z., & Andersen, J. K. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01822-7 · Cited by 10
“These findings emphasize the importance of human-specific models in refining therapeutic strategies for neurodegenerative diseases prior to their advancement to clinical applications.”
Cellular Senescence and Senolytic Agents: Recent Updates on Their Role and Applications
Chandrakar, L., Ambatwar, R., & Khatik, G. L. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266273698231107110956 · Cited by 11
Marca, J. E. L., Kelly, G. L., Strasser, A., & Diepstraten, S. T. (2024) · Developmental Cell · doi:10.1016/j.devcel.2024.06.018 · Cited by 11
Update on developmental therapeutics for acute lymphoblastic leukemia
Smith, M. A. (2009) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-009-0024-3 · Cited by 11
Self-citationHypertonicity-imposed BCL-XL addiction primes colorectal cancer cells for death
Heimer, S., Knoll, G., Steixner, C., Calance, D. N., Trinh, D. T., & Ehrenschwender, M. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.035 · Cited by 10
Parry, N., Busch, C., Assmann, V. D., Cassels, J. E., Hair, A., Helgason, G. V., Wheadon, H., & Copland, M. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01211-1 · Cited by 11
“Along with the crucial role of BCL-xL in the development of platelets [36, 40, 41], this is an important consideration in the translation of BCL-xL inhibitors to cancer therapy with implications for the toxicity profiles of the drugs, although it should be noted that BP-CML blast cells in patients remain undifferentia…”
BackgroundConverging Molecular Mechanisms of Nucleated Cell Death Pathways and Procoagulant Platelet Formation
Li, C., Braun, A., Zu, J., Gudermann, T. W., Mammadova‐Bach, E., & Anders, H. (2025) · Cells · doi:10.3390/cells14141075 · Cited by 10
“Both activated and apoptotic platelets expose PS [24].”
Lieber, J., Dewerth, A., Wenz, J., Kirchner, B., Eicher, C., Warmann, S. W., Fuchs, J., & Armeanu–Ebinger, S. (2012) · Oncology Reports · doi:10.3892/or.2012.2150 · Cited by 9
“Based on this assumption, problematic thrombocytopenia after combination treatment may be weakened, as it is only described with high dosages of BH3 mimetic drugs (33,37,38).”
Ranjit, S., Wang, Y., Zhu, J., Cheepala, S., Schuetz, E. G., Cho, W. J., Xu, B., Robinson, C. G., Wu, G., Naren, A. P., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101017 · Cited by 10
Knockleby, J., Djigo, A. D., Lindamulage, I. K. S., Karthikeyan, C., Trivedi, P., & Lee, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-01058-z · Cited by 9
Machado, V., Serrano, J., & Galián, J. (2016) · Folia Biologica · doi:10.3409/fb64_1.23 · Cited by 10
Gao, G., Moreira, J. D., Das, P., Lin, K., Ge, K., Chen, T., Lu, Y., & Santos, M. A. (2025) · Nature Communications · doi:10.1038/s41467-025-61247-6 · Cited by 8
“To enhance impact and scientific rigor of the manuscript, it would be essential for the authors to expand their experimental validation, providing a more comprehensive analysis that firmly establishes the mechanistic insights proposed.”
Coussens, N. P., Dexheimer, T. S., Silvers, T. E., Sanchez, P. R., Chen, L., Hollingshead, M. G., Takebe, N., Doroshow, J. H., & Teicher, B. A. (2025) · SLAS DISCOVERY · doi:10.1016/j.slasd.2025.100230 · Cited by 8
Debien, E., Hervouet, É., Gautier, F., Juin, P. P., Vallette, F. M., & Cartron, P. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0035-5 · Cited by 9
“…by reducing the number of circulating platelets, whose turnover is regulated by apoptosis, even if ABT-737 seems to be well tolerated in animal model, or by normal hematopoietic and bone marrow cells (Oltersdorf et al. 2005; Konopleva et al. 2006; Mason et al. 2007; Zhang et al. 2007a).”
BackgroundLow carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
Rubio‐Patiño, C., Bossowski, J. P., Villa, E., Mondragón, L., Zunino, B., Proïcs, E., Chiche, J., Bost, F., Verhoeyen, E., & Ricci, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12309 · Cited by 8
“We validated that ABT-737 treatment was effective as it led to thrombocytopenia (Figure 5C), as previously described [28].”
MethodLim, S. T., Tobin, W. O., Murphy, S. J. X., Kinsella, J. A., Smith, D., Lim, S. T., Murphy, S. M., Coughlan, T., Collins, R., O’Neill, D. J., et al. (2020) · Platelets · doi:10.1080/09537104.2020.1850670 · Cited by 8
Marini, B. L., Samanas, L., & Perissinotti, A. J. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216656929 · Cited by 8
“72 Despite promising activity, because of its inhibition of BCLxL, which is critical to maintaining the viability of platelets, studies were halted in pursuit for more BCL2 selective BH3 mimetic.(73,74) Venetoclax (ABT-199) has high binding affinity to BCL2 while sparing BCLxL and BCLw.”
BackgroundMallick, D. J., Korotkov, A., Li, H., Wu, J. Y.-C., & Eastman, A. R. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09469-5 · Cited by 8
Discovery of XZ338, a highly potent BCL-XL degrader
Zhang, X., Thummuri, D., Hu, W., Liu, X., Zhang, P., Zhou, S., Zhou, D., & Zheng, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117624 · Cited by 7
Siddiqui, M. T., & Konopleva, M. Y. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.2008239 · Cited by 7
An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia
Przedborski, M., Sharon, D. M., Cathelin, S., Chan, S. M., & Kohandel, M. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010439 · Cited by 7
BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia
Wu, Y., Zehnle, P. M. A., Rajak, J., Koleci, N., Andrieux, G., Gallego‐Villar, L., Aumann, K., Boerries, M., Niemeyer, C. M., Flotho, C., et al. (2023) · Leukemia · doi:10.1038/s41375-023-02079-5 · Cited by 7
“Mann Whitney: * p < 0.05.”
InfluentialShaverdian, M., Nguyen, N. H., & Li, R. H. L. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1480756 · Cited by 7
“This was shown in two studies in which investigators treated human and canine platelets with ABT-737, an inducer of apoptosis, and found minimal P-selectin expression (29, 30).”
Kwiatek, M., Murthy, G. S. G., Hoffmann, M., Tessoulin, B., Danilov, A. V., Alencar, A. J., Shah, N. N., Ghesquières, H., Gouill, S. L., Jurczak, W. J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.018 · Cited by 7
BH3-mimetic drugs prevent tumour onset in an orthotopic mouse model of hepatoblastoma
Lieber, J., Ellerkamp, V., Vogt, F., Wenz, J., Warmann, S. W., Fuchs, J., & Armeanu–Ebinger, S. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2013.12.007 · Cited by 8
Effect of Uremia and Hemodialysis on Platelet Apoptosis
Sobol, A. B., Kaminska, M., Walczyńska, M., & Walkowiak, B. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612437576 · Cited by 7
“B-cell lymphoma 2 protein family in nucleated cells, induces apoptosis-like process in blood platelets with all characteristic signs of apoptosis, although this agent is ineffective in platelet activation.(16) Another recent article describes the role of calmodulin antagonists, well known as potent apoptosis inducers…”
BackgroundLoss of PUMA ( BBC 3) does not prevent thrombocytopenia caused by the loss of BCL ‐ XL ( BCL 2L1)
Delbridge, A. R. D., Chappaz, S., Ritchie, M. E., Kile, B. T., Strasser, A., & Grabow, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14155 · Cited by 7
“Accordingly, pharmacological inhibition of BCL-XL in mice by treatment with the BH3 mimetic ABT-263 causes thrombocytopenia (Oltersdorf et al, 2005; Mason et al, 2007; Zhang et al, 2007; Roberts et al, 2012).”
BackgroundWang, J., Yao, Y., Zhang, J., Tang, X., Meng, X., Wang, M., Song, L., & Yuan, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.88 · Cited by 7
“Induced platelet apoptosis attenuates platelet reactivity ABT-737, a Bcl-2 Homology 3 (BH3) mimetic, induces platelet apoptosis by inhibiting antiapoptotic Bcl-2 proteins (48-50).”
BackgroundShaverdian, M., Viall, A. K., & Li, R. H. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188776 · Cited by 6
“Studies using the apoptosis inducer, ABT-737, have demonstrated minimal P-selectin expression in platelets undergoing apoptosis, suggesting that platelets do not undergo alpha granule secretion during apoptosis [7,45,80].”
Andrzejewski, S., Winter, M., Garcia, L. E., Akinrinmade, O. A., Marques, F. M., Zacharioudakis, E., Skwarska, A., Aguirre‐Ghiso, J. A., Konopleva, M. Y., Zheng, G., et al. (2025) · Cells · doi:10.3390/cells14191557 · Cited by 6
“Existing inhibitors of BCL-XL have potent efficacy against tumor cells but are limited by thrombocytopenia-related adverse effects due to the dependence of platelets on BCL-XL for survival [57,58].”
Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors
Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114526 · Cited by 6
Apoptosis of Platelets Inhibited By Herba Sarcandrae Extract through the Mitochondria Pathway
Zhu, X., Jiang, Y., Zheng, Q., Zhang, A., Shi, L., Xia, L., & Luo, M. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/1956902 · Cited by 6
“Besides, platelet apoptosis causes the PS exposure, vesicles formation of the cell membrane, and the release of plateletmicroparticles [30].”
BackgroundCofilin‐1–induced actin reorganization in stored platelets
Dasgupta, S. K., & Thiagarajan, P. (2020) · Transfusion · doi:10.1111/trf.15747 · Cited by 6
“As platelets age, degradation of Bcl-xL triggers Bak-mediated phosphatidylserine exposure and clearance from the circulation in mice.(8) ABT-737, a synthetic Bcl-xL antagonist, induces apoptotic changes and phosphatidylserine exposure by preventing the antiapoptotic effect of Bcl-xL,(9) thus mimicking the mitochondria…”
BackgroundBui, I., Baritaki, S., Libra, M., Zaravinos, A., & Bonavida, B. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0250 · Cited by 6
“In studies on the anti-apoptotic Bcl-2 inhibitor, ABT-263, effects were shown to be limited by induced thrombocytopenia following dosing (Petros et al., 2010; Suvarna et al., 2019; Zhang et al., 2007).”
Mammalian apoptosis in a parasitic worm
Rosenberg, S. H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104151108 · Cited by 5
“Bcl-2 proteins are involved in normal tissue homeostasis (17), and hence selectivity for the schistosome protein will likely be required for any therapeutic agent.”
BackgroundSelf-citationRola wenetoklaksu w leczeniu chorych na przewlekłą białaczkę limfocytową
Puła, B., & Jamroziak, K. (2017) · Hematologia · doi:10.5603/hem.2017.0003 · Cited by 5
Bcl-2 Family and Their Therapeutic Potential
Liu, Q., Chi, X., Leber, B. F., & Andrews, D. W. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9302-0_4 · Cited by 7
“The most common adverse event after ABT-737 and ABT-263 treatments is thrombocytopenia, which is actually an on-target toxicity effect due to the critical dependence of platelet development and survival on the function of Bcl-XL [ 197 , 198 ].”
BackgroundRepsold, L., Pool, R., Karodia, M., Tintinger, G. R., Becker, P., & Joubert, A. M. (2021) · Cell Biochemistry and Function · doi:10.1002/cbf.3625 · Cited by 5
“Platelet apoptosis is closely associated with platelet activation, as platelet activation is accompanied by PS externalization, cell shrinkage and formation of microparticles which is suggestive of the apoptotic process.(28) F IGURE 5 Line graph comparison of mean fluorescent intensity of chronic myeloid leukaemia (CM…”
BackgroundLi, J., Song, N., Ma, R., & Qu, X. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.118831 · Cited by 5
Multi-functional platelets: translating biological functions into therapeutic applications
Zou, C., Deng, Y.-T., Lin, X.-R., & Xie, H.-Q. (2025) · Vessel Plus · doi:10.20517/2574-1209.2025.114 · Cited by 5
A glycoprotein VI signaling defect in newly formed platelets generated in stress thrombopoiesis
Hyslop, S. R., Corbin, J. E., Gangatirkar, P., Lebois, M., Au, A. E., Moujalled, D., Pleines, I., Sutherland, K. D., Andrews, R. K., Gardiner, E. E., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.02.035 · Cited by 4
Prechel, M., Escalante, V., Drenth, A. F., & Walenga, J. M. (2011) · Platelets · doi:10.3109/09537104.2011.592957 · Cited by 4
Advances in the pharmacological management of acute myeloid leukemia in adults
Numan, Y., Abaza, Y., Altman, J. K., & Platanias, L. C. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2111212 · Cited by 4
“This drug was first studied in CLL but it’s development in AML has been complicated by the development of thrombocytopenia, due to its inhibitory activity on BCL-XL which is also present on platelets [15].”
BackgroundLeytin, V., Gyulkhandanyan, A. V., & Freedman, J. J. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618778140 · Cited by 4
Acute toxicity analysis of an inhibitor of BCL2, Disarib, in rats
Sharma, S., Varsha, K. K., Ray, U., Siddiqua, H., Jose, A. E., Muninarasimaiah, S., Raghavan, S. C., & Choudhary, B. (2021) · Scientific Reports · doi:10.1038/s41598-021-89387-x · Cited by 4
Wright, J. R., Jones, S., Sasikumar, P., Kaczmarek, L. K., Forsythe, I. D., Farndale, R. W., Gibbins, J. M., & Mahaut‐Smith, M. P. (2021) · Platelets · doi:10.1080/09537104.2021.1942818 · Cited by 4
New insights into binding of natural chalcones to Bcl-2, Bcl-xL and Mcl-1 anti-apoptotic proteins
Ćirin, D. M., & Krstonosic, V. S. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130700 · Cited by 4
Shifting Paradigms in the Treatment of Chronic Lymphocytic Leukemia
Thompson, P. A., Shpall, E. J., & Keating, M. J. (2015) · Future Oncology · doi:10.2217/fon.14.288 · Cited by 3
Miyan, J., Vudatha, V., Cao, L., Zhang, P., Zheng, G., Zheng, L., Trevino, J., Zhou, D., & Khan, S. (2026) · Cancers · doi:10.3390/cancers18060920 · Cited by 3
Pharmacodynamic Studies in Early Phase Drug Development
Camidge, D. R., Doebele, R. C., & Jimeno, A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7358-0_9 · Cited by 3
“Recently, it has been discovered that platelets resist senescence through upregulation of BCl-Xl and that continuous dosing of dogs with a Bcl-2 family inhibitor with activity against BCl-Xl cause a rapid decrease in platelet levels with a slow return to normal levels as younger platelets repopulate the blood [83, 84].”
BackgroundNevzorova, T. A., Mordakhanova, E. R., Andrianova, I. A., & Litvinov, R. I. (2015) · Genes and Cells · doi:10.23868/gc120493 · Cited by 3
Gomez, L. S., & Jurk, D. (2024) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-66768-8_5 · Cited by 4
Cell Death in the Hematopoietic System
Josefsson, E. C., & Kile, B. T. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-381-7_19 · Cited by 3
Mechanism-based toxicity studies for drug development
Otieno, M. A., & Lehman‐McKeeman, L. D. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511779053.014 · Cited by 3
Death-defying apoptotic caspases in thrombopoiesis
Cantor, A. B. (2012) · Blood · doi:10.1182/blood-2012-02-410423 · Cited by 3
Molecular mechanisms regulating platelet clearance and thrombopoietin production
Grozovsky, R., Giannini, S., Falet, H., & Hoffmeister, K. M. (2015) · ISBT Science Series · doi:10.1111/voxs.12144 · Cited by 3
31st Annual GP2A Medicinal Chemistry Conference
Primas, N., Castera‐Ducros, C., Paoli-Lombardo, R., Curti, C., Mathias, F., Rathelot, P., Marchand, P., & Vanelle, P. (2024) · Drugs and Drug Candidates · doi:10.3390/ddc3010013 · Cited by 3
Semenova, G., Frank, S. B., Dumpit, R. F., Han, W., Coleman, I. M., Gulati, R., Dirican, C. D., Arman, T., Maruwan, J., Morrissey, C. M., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci200438 · Cited by 2
“Prior studies have established that inhibition of BCL-XL leads to on-target hematologic toxicity, most notably thrombocytopenia, reflecting the dependence of platelets on BCL-XL for survival (57, 58).”
Chen, C., Hsia, C., Huang, W.-C., Chang, C.-C., Darmanto, A. G., & Sheu, J. (2025) · Biomolecules · doi:10.3390/biom15121638 · Cited by 2
“In contrast, inhibition of anti-apoptotic Bcl-2 family proteins with ABT-737 induces classical apoptotic events—including cytochrome c release, caspase-3 activation, and PS exposure—without directly triggering platelet activation in vitro, while also promoting platelet clearance in vivo [29].”
Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma
Zeng, Q., Zhang, Y., Yang, Y., Liu, X., Dong, X., Pan, Y., Hu, L., Zhang, A., Yang, J., Luo, Q., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04671-9 · Cited by 2
“Therapeutic targeting of BCL-XL has historically been constrained by on-target thrombocytopenia, as platelets rely on BCL-XL for survival [14].”
The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke
Falahatgaroshibi, D., Baixauli-Martín, J., Burguete, M. C., López‐Morales, M. A., Aliena‐Valero, A., Peris, J., & Salom, J. B. (2026) · Pharmaceuticals · doi:10.3390/ph19030431 · Cited by 2
“Navitoclax-induced thrombocytopenia is consistent with its mechanism of action by inhibiting Bcl-2 family proteins, which are essential for platelet survival [24].”
Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions
Ko, K. H., Gelfer, R., Wheat, J. C., & Cai, S. F. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16030169 · Cited by 2
“Despite these data, BCL-XL is known to be required for platelet survival and on-target thrombocytopenia occurs in a substantial number of patients, limiting clinical utility [27,28].”
Cell death and the immune responses of the sipunculan worm Themiste petricola
Blanco, G. A. C. (2010) · Invertebrate survival journal · Cited by 2
BCL-W makes only minor contributions to MYC-driven lymphoma development
Diepstraten, S. T., Marca, J. E. L., Chang, C. W. T., Young, S., Strasser, A., & Kelly, G. L. (2023) · Oncogene · doi:10.1038/s41388-023-02804-5 · Cited by 2
“Clinical deployment of ABT-263/ Navitoclax has been challenging due to BCL-XL being required for platelet survival [10, 11], though chemically conjugating the BCL-XL-specific BH3-mimetic AZD4320 with a PEGylated polylysine dendrimer improved its targeting to the lymphatic system, thereby reducing on-target platelet to…”
BackgroundDeath regulates platelet birth and life
Hoffmeister, K. M. (2012) · Blood · doi:10.1182/blood-2012-04-417295 · Cited by 2
Karagiannis, P., Sugimoto, N., & Eto, K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00066-7 · Cited by 2
Ghasemzadeh, M., Heidari, N., Naghinezhad, J., Ghasemzadeh, A., & Hosseini, E. (2025) · Cancer Medicine · doi:10.1002/cam4.71270 · Cited by 1
“However, the lack of interference of ABT-737 with the pro-inflammatory potential of platelets can be considered a positive aspect of this drug [54, 55].”
Shaverdian, M., Nguyen, N., Fitzgerald, S., Grubb, L., Stern, J. A., & Li, R. H. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-46991-z · Cited by 1
“However, while procoagulant platelets have surface expression of P-selectin, apoptotic platelets do not undergo alpha-granule release, and is, therefore, recommended as a surface marker by the International Society of Thrombosis and Haemostasis 30,60,61 .”
Structure-Based Discovery of Potent BCL-XL Inhibitors through Rescaffolding
Timari, M., Paczal, A., Herner, A., Molnár, M., Madarász, Z., Nyerges, M., Bedford, S. T., Brooks, T., Davidson, J. E. P., Daniels, Z., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00865 · Cited by 1
BCL2 Inhibitors: Insights into Resistance
Anderson, M. A., Roberts, A. W., & Seymour, J. F. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-75184-9_2 · Cited by 1
Shpakova, V., Gambaryan, S. P., Рукояткииа, Н. И., & Кривченко, А. И. (2018) · Российский физиологический журнал им И М Сеченова · doi:10.7868/s0869813918090095 · Cited by 1
Pharmacologic Features of Drugs Targeting BCL 2 Family Members
Lue, J. K., & O’Connor, O. A. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch11 · Cited by 1
Bcl-2 Family: Translational Aspects
Bose, P., & Grant, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_4 · Cited by 1
Lérida‐Viso, A. (2023) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/194709 · Cited by 1
Jatal, R. (2021) · theses.fr (ABES) · doi:10.70675/7299ae44z37f8z4e79z8e0dz67e48edb7144 · Cited by 3
Platelet procoagulant acitivity: focus on calcium entry and phospholipid scrambling
van Kruchten, R. (2014) · Research Publications (Maastricht University) · doi:10.26481/dis.20140117rk
Regulation of mast cell survival and apoptosis
Karlberg, M. (2008) · Figshare
Barros, F. E. V. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2015.tde-31032015-163547
Manipulation of cell death pathways in cancer
Bray, K. (2011) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3bp01xm · Cited by 2
The Pathophysiology of Immune Thrombocytopenic Purpura
Kuter, D. J. (2009)
O’Connor, O. A. (2010)
Regulation of Megakaryocyte and Platelet Survival
Au, A. E., Lebois, M., Pleines, I., & Josefsson, E. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-39562-3_9
Cartlidge, R. C. (2015) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Metadata
- Authors
- Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., Preusser, L. C., Reinhart, G. A., Smith, M. L., Rosenberg, S. H., Elmore, S. W., & Tse, C.
- Affiliations
- Abbott (United States) (US)
- Corresponding author
- Elmore, S W
- Tse, C
- Venue
- Cell Death & Differentiation
- Published
- 2007-01-05
- Volume
- 14
- Issue
- 5
- Pages
- 943-951
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1976197588
- Cited by
- 427
- References
- 32
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 17 · 2023: 20 · 2022: 28 · 2021: 38 · 2020: 31 · 2019: 15 · 2018: 24 · 2017: 27 · 2016: 27 · 2015: 23 · 2014: 27 · 2013: 26 · 2012: 21
- FWCI
- 11.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cell Death and Differentiation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Keywords
- platelet survival, Bcl-2 family proteins, ABT-737, platelet clearance, caspase-3 activation, cytochrome c release, phosphatidylserine exposure, mitochondrial membrane potential, reticuloendothelial system, hepatic clearance, platelet activation, hemostasis
- MeSH terms
- Animals, Biphenyl Compounds, Blood Platelets, Cell Separation, Cell Survival, Cytoplasmic Granules, Dogs, Dose-Response Relationship, Drug, Exocytosis, Flow Cytometry, Humans, Liver, Male, Nitrophenols, Phosphatidylserines, Piperazines, Platelet Aggregation, Platelet Count, Sulfonamides, Apoptosis, Proto-Oncogene Proteins c-bcl-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.